ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: BDSI

BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone

BDSI’s cancer pain product preps for Europe, triggers $2.5M milestone

May 21, 2012 11:00 am by | 0 Comments

The breakthrough cancer pain treatment developed by BioDelivery Sciences (NASDAQ:BDSI) International is making progress toward entering the European market, triggering a $2.5 milestone payment from BDSI’s drug partner Meda Pharmaceuticals.The ... Read more
Patent award to BDSI triggers $15M milestone payment from Endo Pharma

Patent award to BDSI triggers $15M milestone payment from Endo Pharma

April 17, 2012 10:30 am by | 0 Comments

A drug delivery technology patent awarded to BioDelivery Sciences International (NASDAQ:BDSI) has triggered a $15 million milestone payment from drug partner Endo Pharmaceuticals (NASDAQ:ENDP).Raleigh, North Carolina-based BDSI said today that ... Read more
FDA concerns delay relaunch of BDSI cancer pain product Onsolis

FDA concerns delay relaunch of BDSI cancer pain product Onsolis

March 12, 2012 12:34 pm by | 0 Comments

Plans to relaunch breakthrough cancer pain treatment Onsolis are now delayed indefinitely until BioDelivery Sciences International (NASDAQ:BDSI) can work out manufacturing issues raised by the U.S. Food and Drug Administration.Over ... Read more
Patent decision favors BDSI; USPTO rejects 222 MonoSol Rx claims

Patent decision favors BDSI; USPTO rejects 222 MonoSol Rx claims

March 7, 2012 3:40 pm by | 0 Comments

Specialty pharmaceutical company BioDelivery Sciences International (NASDAQ:BDSI) can now claim patent victories against all three patent challenges levied by a rival in a long-running patent dispute.The U.S. Patent and Trademark ... Read more
Drug delivery technology from BDSI withstands MonoSol patent challenge

Drug delivery technology from BDSI withstands MonoSol patent challenge

February 22, 2012 12:32 pm by | 0 Comments

Drug delivery technology developed by BioDelivery Sciences International (NASDAQ:BDSI) has withstood another patent challenge from competitor MonoSol Rx.Specialty pharmaceutical company BDSI said that the U.S Patent and Trademark Office has ... Read more
BDSI to get patent; issuance triggers $15M milestone from partner Endo

BDSI to get patent; issuance triggers $15M milestone from partner Endo

February 16, 2012 4:33 pm by | 0 Comments

BioDelivery Sciences International (NASDAQ:BDSI) stands to gain a $15 million milestone payment after getting word that its drug delivery technology will be granted a patent for two drug treatments.The U.S. ... Read more
$40M stock offering filed by BioDelivery Sciences International

$40M stock offering filed by BioDelivery Sciences International

February 6, 2012 12:20 pm by | 0 Comments

A month after licensing a clinical-stage chronic pain treatment to Endo Pharmaceuticals (NASDAQ:ENDP) in a deal worth up to $180 million, BioDelivery Sciences International (NASDAQ: BDSI) is now preparing an ... Read more
Chronic pain treatment from BDSI licensed to Endo Pharma in $180M deal

Chronic pain treatment from BDSI licensed to Endo Pharma in $180M deal

January 6, 2012 12:01 pm by | 1 Comments

The investigational chronic pain treatment from BioDelivery Sciences International (NASDAQ:BDSI) that failed in a late-stage clinical trial now has a partner and a plan that salvages the drug program and ... Read more
How FDA changes to ‘REMS’ rules helps BioDelivery Sciences

How FDA changes to ‘REMS’ rules helps BioDelivery Sciences

December 30, 2011 3:14 pm by | 0 Comments

Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs ... Read more
Patent ruling favors BDSI; MonoSol still claims infringement on other patents

Patent ruling favors BDSI; MonoSol still claims infringement on other patents

November 28, 2011 1:49 pm by | 0 Comments

BioDelivery Sciences International (NASDAQ:BDSI) has a patent victory against a competitor who claims the North Carolina pharmaceutical company’s drug delivery platform infringes on its technology.The United States Patent and Trademark ... Read more
BDSI needs partner to finance round 2 of phase 3 trials in chronic pain

BDSI needs partner to finance round 2 of phase 3 trials in chronic pain

November 15, 2011 5:01 pm by | 0 Comments

BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as it works to find a drug partner before it runs out of both.The company has ... Read more
BDSI opioid dependence drug NDA planned for late 2012

BDSI opioid dependence drug NDA planned for late 2012

November 10, 2011 11:46 am by | 0 Comments

BioDelivery Sciences International (NASDAQ:BDSI) has started testing how its experimental opioid dependence treatment is handled by the human body as it moves forward with its plans to break into the ... Read more
BDSI: Pharma partners still interested in pain drug’s $500M potential

BDSI: Pharma partners still interested in pain drug’s $500M potential

September 29, 2011 11:08 am by | 0 Comments

Before BioDelivery Sciences International (NASDAQ:BDSI) released early phase 3 clinical trial results showing its pain drug missed the primary target of its study, the company had gotten as far as ... Read more
BDSI pain drug fails in phase 3 trials but company plans new study

BDSI pain drug fails in phase 3 trials but company plans new study

September 28, 2011 11:23 pm by | 0 Comments

A pain drug candidate from BioDelivery Sciences International (NASDAQ:BDSI) failed to perform better than a placebo in phase 3 clinical trials, according to preliminary trial results released by the biopharmaceutical ... Read more
BDSI’s opioid-addiction drug candidate aims to challenge market leader RB

BDSI’s opioid-addiction drug candidate aims to challenge market leader RB

September 6, 2011 1:28 pm by | 1 Comments

An opioid-dependence treatment being developed by BioDelivery Sciences International (NASDAQ:BDSI) is on track for a New Drug Application filing in the second half of 2012, making it a contender to ... Read more